These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30803073)

  • 41. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
    Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
    Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The blood-brain barrier: clinical implications for drug delivery to the brain.
    De Boer AG; Breimer DD
    J R Coll Physicians Lond; 1994; 28(6):502-6. PubMed ID: 7884704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic Investigation of Quetiapine Transport across Blood-Brain Barrier Mediated by Lipid Core Nanocapsules Using Brain Microdialysis in Rats.
    Carreño F; Paese K; Silva CM; Guterres SS; Dalla Costa T
    Mol Pharm; 2016 Apr; 13(4):1289-97. PubMed ID: 26905300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthetic carriers for vascular delivery of protein therapeutics.
    Dziubla TD; Muzykantov VR
    Biotechnol Genet Eng Rev; 2006; 22():267-98. PubMed ID: 18476335
    [No Abstract]   [Full Text] [Related]  

  • 45. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
    Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
    Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ultrasound-induced blood-brain barrier opening for drug delivery.
    Alonso A
    Front Neurol Neurosci; 2015; 36():106-15. PubMed ID: 25531667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
    Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
    Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.
    Govender T; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Modi G; Naidoo D; Pillay V
    Pharm Dev Technol; 2017 Jun; 22(4):476-486. PubMed ID: 27268737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
    Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
    Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
    Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
    Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain drug delivery systems.
    Jiang X
    Pharm Res; 2013 Oct; 30(10):2427-8. PubMed ID: 23921487
    [No Abstract]   [Full Text] [Related]  

  • 53. Nanoparticle transport across the blood brain barrier.
    Grabrucker AM; Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    Tissue Barriers; 2016; 4(1):e1153568. PubMed ID: 27141426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CNS therapeutics: Immune cells break the barriers.
    Thai K; Prat A
    Sci Transl Med; 2023 Nov; 15(721):eadh1150. PubMed ID: 37939159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
    Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
    J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The CNS as a target for peptides and peptide-based drugs.
    Banks WA
    Expert Opin Drug Deliv; 2006 Nov; 3(6):707-12. PubMed ID: 17076593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vector-mediated drug delivery to the brain.
    Temsamani J; Rousselle C; Rees AR; Scherrmann JM
    Expert Opin Biol Ther; 2001 Sep; 1(5):773-82. PubMed ID: 11728213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity.
    Hemmelmann M; Metz VV; Koynov K; Blank K; Postina R; Zentel R
    J Control Release; 2012 Oct; 163(2):170-7. PubMed ID: 22981565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.